Related Experiment Video

Updated: Jul 10, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

One size does not fit all: the need for a continuous measure for glycemic control in diabetes

David C Aron1, Leonard M Pogach

  • 1Center for Quality Improvement Research, Louis Stoker Cleveland Veterans Affairs Medical Center, USA.

Joint Commission Journal on Quality and Patient Safety
|November 23, 2007
PubMed

Insights

A continuous measure of glycosylated hemoglobin (A1C) better reflects diabetes care quality than a simple threshold. This approach offers a more accurate assessment of population health and healthcare performance for diabetes management.

Area of Science:

  • Diabetes management and quality assessment in healthcare.

Background:

  • Glycosylated hemoglobin (A1C) is a primary measure for assessing glycemic control in diabetes care.
  • Historically, dichotomous thresholds (e.g., A1C > 9%) have been used to define poor glycemic control, setting a single standard for all patients.

Purpose of the Study:

  • To evaluate the limitations of dichotomous A1C thresholds in accurately reflecting population health outcomes.
  • To propose a continuous measure of A1C for a more comprehensive quality assessment in diabetes care.

Main Methods:

  • The study conceptually evaluates the impact of risk reduction for micro- and macrovascular complications, noting a log-linear relationship with A1C levels.
  • It contrasts dichotomous 'all or none' quality measures with a continuous assessment model.

Main Results:

  • Dichotomous A1C thresholds may not accurately represent the impact of care on population health due to the non-linear relationship between A1C and complication risk.
  • A continuous A1C measure provides a more nuanced evaluation, acknowledging greater benefits from improved control in patients with higher initial A1C levels.

Conclusions:

  • A continuous measure of A1C is superior to a dichotomous threshold for capturing the complexity of glycemic control at a population level.
  • This approach can better incorporate the Institute of Medicine's quality domains: effectiveness, equity, safety, patient-centeredness, timeliness, and efficiency.
Abstract

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...